Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.50 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896879 | 0.95 | ALDH1A1 (0.50) | PREPDRD1ALDH1A1CYP2A6CA12 | |
| SCHEMBL6027756 | 0.90 | ALDH1A1 (0.46) | PREPDRD1ALDH1A1CYP2A6CA12 | |
| SCHEMBL17494817 | 0.88 | ALDH1A1 (0.44) | PREPDRD1ALDH1A1CYP2A6CA12 | |
| 4-Hydroxybenzaldehyde SCHEMBL17494799 | 0.87 | ALDH5A1 (0.52) | PREPALDH1A1CYP2A6CA12CA1 | |
| SCHEMBL23491348 | 0.85 | PREP (0.57) | PREPCA12CA1CA9KDM4E | |
| Piperidine SCHEMBL1082681 | 0.82 | PREP (0.41) | PREPALDH1A1CYP2A6CA12CA1 | |
| SCHEMBL4892044 | 0.81 | PREP (0.41) | PREPDRD1ALDH1A1CA12CA1 | |
| SCHEMBL1161803 | 0.80 | CA12 (0.56) | PREPALDH1A1CYP2A6CA12CA1 | |
| SCHEMBL7189378 | 0.80 | CA12 (0.46) | PREPALDH1A1CA12CA1CA9 | |
| SCHEMBL6763899 | 0.79 | PREP (0.53) | PREPALDH1A1CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | WYETH (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | WYETH (US) | 2008-02-07 | — | — | US | disclosed |
| US-7279600-B2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279600-B2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1808429-A2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | Wyeth a Corporation of the State of Delaware (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1620392-B1 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1620392-A2 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | Wyeth (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050020676-A1 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH | 2005-01-27 | — | — | US | disclosed |
| WO-2004099122-A2 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | ESR1, ESR2, ESRRB | PREP 2705/4885DRD1 793/4885ALDH1A1 348/4885 |
| US-20050020676-A1 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | ESR1, ESR2, ESRRB | PREP 2705/4885DRD1 793/4885ALDH1A1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.